Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Adjunct treatment with anastrozole in children with congenital adrenal hyperplasia (CAH) delays the rate of bone maturation and increases the predicted adult height over 6 years, with no significant ...

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

12,128,055) for its innovative T+Ai combination therapy?a novel composition of testosterone and anastrozole in a long-acting, slow-release subcutaneous implant. "Our new patent for T+Ai is a critical ...

The product, T+Ai™ , is a combination of two registered agents (testosterone and anastrozole, a low dose aromatase inhibitor) that when dosed, provides three months of continuous medication ...

Sanofi’s BTK in­hibitor rilz­abru­ti­nib helped 23% of adults with a rare au­toim­mune blood dis­or­der achieve tar­get platelet counts in a Phase 3 tri­al, com­pared to … ...

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings Rilzabrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a protein that ...

Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, 10770 Science Center Drive, La Jolla, California 92121, United States ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant ...

Aromatase inhibitors (AIs) are becoming the hormonal ... efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen ...